[go: up one dir, main page]

PE20110412A1 - Formulacion farmaceutica de eprosartan - Google Patents

Formulacion farmaceutica de eprosartan

Info

Publication number
PE20110412A1
PE20110412A1 PE2011000022A PE2011000022A PE20110412A1 PE 20110412 A1 PE20110412 A1 PE 20110412A1 PE 2011000022 A PE2011000022 A PE 2011000022A PE 2011000022 A PE2011000022 A PE 2011000022A PE 20110412 A1 PE20110412 A1 PE 20110412A1
Authority
PE
Peru
Prior art keywords
pharmaceutical formulation
eprosartan
hydrochlorothiazide
diuretic
hypertension
Prior art date
Application number
PE2011000022A
Other languages
English (en)
Inventor
Paulus A J Link
Der Hulst Marcellus M Van
Gerhard-Wilhelm Bielenberg
Den Akker Cornelis R Van
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of PE20110412A1 publication Critical patent/PE20110412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE CONTIENE: A) EPROSARTAN ACIDO EN UNA CANTIDAD DE 410MG A 490MG; B) MONOHIDRATO DE ALFA LACTOSA 200M; C) CELULOSA MICROCRISTALINA SILICIFICADA; D) ALMIDON; E) N-VINIL-2-PIRROLIDONA ENTRECRUZADA; Y OPCIONALMENTE F) UN DIURETICO TAL COMO HIDROCLOROTIAZIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE HIPERTENSION, FALLA CARDIACA CONGESTIVA, FALLA RENAL
PE2011000022A 2008-07-11 2009-07-09 Formulacion farmaceutica de eprosartan PE20110412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08160211 2008-07-11

Publications (1)

Publication Number Publication Date
PE20110412A1 true PE20110412A1 (es) 2011-07-04

Family

ID=39731507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000022A PE20110412A1 (es) 2008-07-11 2009-07-09 Formulacion farmaceutica de eprosartan

Country Status (21)

Country Link
US (2) US20100010062A1 (es)
EP (1) EP2317987B1 (es)
JP (1) JP2011527314A (es)
KR (1) KR20110031226A (es)
CN (1) CN102088961A (es)
AR (1) AR072477A1 (es)
AU (1) AU2009268044A1 (es)
BR (1) BRPI0915455A2 (es)
CA (1) CA2730008A1 (es)
CO (1) CO6331424A2 (es)
DO (1) DOP2011000011A (es)
EA (1) EA201170182A1 (es)
EC (1) ECSP10010701A (es)
IL (1) IL210001A0 (es)
MX (1) MX2011000349A (es)
NZ (1) NZ589904A (es)
PE (1) PE20110412A1 (es)
TW (1) TW201006826A (es)
UA (1) UA100434C2 (es)
WO (1) WO2010003996A1 (es)
ZA (1) ZA201100223B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190051T1 (de) * 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
PL340587A1 (en) * 1997-11-17 2001-02-12 Smithkline Beecham Corp Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
HUP0103000A3 (en) * 1998-07-20 2002-08-28 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form and process for their preparation
EP1694305B1 (en) * 2003-12-01 2019-10-16 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
WO2005084666A1 (en) * 2004-03-02 2005-09-15 Abeille Pharmaceuticals, Inc. Co-formulations of kits of bioactive agents
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2628955A1 (en) * 2005-11-07 2007-05-18 Edward S. Wilson Compositions of stabilized ramipril in combination with another active agent

Also Published As

Publication number Publication date
US20100010062A1 (en) 2010-01-14
CN102088961A (zh) 2011-06-08
EP2317987B1 (en) 2014-04-23
DOP2011000011A (es) 2011-01-31
AR072477A1 (es) 2010-09-01
EP2317987A1 (en) 2011-05-11
IL210001A0 (en) 2011-02-28
CO6331424A2 (es) 2011-10-20
MX2011000349A (es) 2011-02-22
BRPI0915455A2 (pt) 2017-06-27
ECSP10010701A (es) 2011-01-31
UA100434C2 (en) 2012-12-25
EA201170182A1 (ru) 2011-08-30
CA2730008A1 (en) 2010-01-14
NZ589904A (en) 2012-08-31
JP2011527314A (ja) 2011-10-27
WO2010003996A1 (en) 2010-01-14
US20120302555A1 (en) 2012-11-29
ZA201100223B (en) 2011-10-26
AU2009268044A1 (en) 2010-01-14
KR20110031226A (ko) 2011-03-24
TW201006826A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
CL2008001201A1 (es) Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca.
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
CL2012002521A1 (es) Composicion farmaceutica que comprende un inhibidor de dpp iv seleccionado de un grupo definido, un primer diluyente, un segundo diluyente: manitol, un segundo diluyente: almidon pregelatinizado, un aglutinante y un lubricante; util en el tratamiento de diabetes. (divisional de la sol. 1260-07).
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
NZ595073A (en) Proline derivatives as cathepsin inhibitors
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
BRPI0916418A2 (pt) Composição, e, método de produção de uma composição de fluido espessada substancialmente não-citotóxica
CL2009000889A1 (es) Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
PE20201496A1 (es) Composiciones y metodos para tratar anemia
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
EA200901619A1 (ru) Способ получения телмисартана
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20091746L (no) Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper
PE20060768A1 (es) Composicion farmaceutica que comprende hidroclorotiazida y telmisartano
CR20110209A (es) Composición farmacéutica sólida
CR11398A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
EA201270204A1 (ru) Таблетка
PE20180324A1 (es) 1h-pirazol-5-olato sodico sustituido
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed